Christina Charles‐Schoeman

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

Medicine, Pharmacology, Pharmacotherapy +12

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 395 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis

Christina Charles‐Schoeman, Yuen Yin Lee, Víctor Grijalva et al. · Annals of the Rheumatic Diseases · 2012 · 227 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen et al. · Annals of the Rheumatic Diseases · 2020 · 221 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

Maureen McMahon, Jennifer Grossman, Brian J. Skaggs et al. · Arthritis & Rheumatism · 2009 · 216 citations · Full text

Veterinary Medicine, Pathobiology, Inflammation +11